COMPASS PATHWAYS PLC

Compass Pathways Plc shares dip 0.5% as the psilocybin‑therapy company trades near $11.84, amid a 19.9% YTD decline and a $1.6 bn market cap.

Compass Pathways surges 3.35% amid volatility, offering a brief upside hint in psilocybin therapy for treatment‑resistant depression.

Compass Pathways shares climb 3.3% amid market volatility, showing resilience as psilocybin‑based therapeutics gain investor interest and potential upside.